A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

NCT03456063 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

453

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small-Cell Lung

Interventions

DRUG: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
DRUG: Placebo Comparator
DRUG: Nab-paclitaxel
DRUG: Pemetrexed
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Gemcitabine

Sponsor

Hoffmann-La Roche